Safety evaluation of zotepine for the treatment of schizophrenia. 2010

Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
Ludwig-Maximilians-University Munich, Department of Psychiatry and Psychotherapy, Munich, Germany. riedel@med.uni-muenchen.de

BACKGROUND Atypical antipsychotics have become the first-line treatment for patients suffering from schizophrenia in the industrialized world. Given the frequent necessity of a life-long enduring antipsychotic treatment, the compounds' safety profile is of great importance for patients and caregivers. Zotepine is an antipsychotic with atypical properties and previous data have suggested a very favorable side effect profile. METHODS The aim of this review is to provide a broad knowledge base on the safety profile of zotepine deriving from currently available research results published in English medical databases. The focus of this research reports starts in the 1990s with zotepine's approval in Europe. RESULTS This paper incorporates data on placebo-controlled studies of zotepine as well as studies with comparator compounds also beyond the diagnostic boarder of schizophrenia regarding zotepine's safety. CONCLUSIONS The take home message of this safety evaluation of zotepine is that compared to typical compounds zotepine induces less extrapyramidal side effects; however, in terms of comparing zotepine's safety with other atypical antipsychotics more studies are needed to draw final conclusions.

UI MeSH Term Description Entries
D008297 Male Males
D003988 Dibenzothiepins
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001523 Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function. Mental Illness,Psychiatric Diseases,Psychiatric Disorders,Psychiatric Illness,Behavior Disorders,Diagnosis, Psychiatric,Mental Disorders, Severe,Psychiatric Diagnosis,Illness, Mental,Mental Disorder,Mental Disorder, Severe,Mental Illnesses,Psychiatric Disease,Psychiatric Disorder,Psychiatric Illnesses,Severe Mental Disorder,Severe Mental Disorders
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical

Related Publications

Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
October 2006, Schizophrenia research,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
January 2000, The Cochrane database of systematic reviews,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
October 2006, The Cochrane database of systematic reviews,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
February 1987, Pharmacopsychiatry,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
October 1987, Journal of clinical psychopharmacology,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
February 1987, Pharmacopsychiatry,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
October 2010, The Cochrane database of systematic reviews,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
January 2010, The Cochrane database of systematic reviews,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
January 2000, International journal of psychiatry in clinical practice,
Michael Riedel, and Richard Musil, and Florian Seemüller, and Ilja Spellmann, and Hans-Jürgen Möller, and Rebecca Schennach-Wolff
January 2016, Expert opinion on drug safety,
Copied contents to your clipboard!